Presentation is loading. Please wait.

Presentation is loading. Please wait.

The Farnesyl Transferase Inhibitor Lonafarnib Inhibits mTOR Signaling and Enforces Sorafenib-Induced Apoptosis in Melanoma Cells  Heike Niessner, Daniela.

Published byMax Davidsen Modified over 6 years ago

Similar presentations

Presentation on theme: "The Farnesyl Transferase Inhibitor Lonafarnib Inhibits mTOR Signaling and Enforces Sorafenib-Induced Apoptosis in Melanoma Cells  Heike Niessner, Daniela."— Presentation transcript:

1 The Farnesyl Transferase Inhibitor Lonafarnib Inhibits mTOR Signaling and Enforces Sorafenib-Induced Apoptosis in Melanoma Cells  Heike Niessner, Daniela Beck, Tobias Sinnberg, Konstantinos Lasithiotakis, Evelyn Maczey, Jeannette Gogel, Sascha Venturelli, Alexander Berger, Mario Mauthe, Mahmoud Toulany, Keith Flaherty, Martin Schaller, Dirk Schadendorf, Tassula Proikas-Cezanne, Birgit Schittek, Claus Garbe, Dagmar Kulms, Friedegund Meier  Journal of Investigative Dermatology  Volume 131, Issue 2, Pages (January 2011) DOI: /jid Copyright © 2011 The Society for Investigative Dermatology, Inc Terms and Conditions

2 Figure 1 Lonafarnib inhibits farnesylation of the farnesyl transferase target HDJ2. Melanoma cells (BLM, MV3, MEWO, and SKMel19) were incubated with increasing concentrations of lonafarnib (0.1, 1, and 5μM) for 24hours, followed by western blotting with anti-HDJ2 to detect the farnesylated (faster migrating band) and unfarnesylated (slower migrating band) forms of this farnesyl transferase target. Journal of Investigative Dermatology  , DOI: ( /jid ) Copyright © 2011 The Society for Investigative Dermatology, Inc Terms and Conditions

3 Figure 2 Lonafarnib and sorafenib synergistically inhibit melanoma cell growth. Growth assay (4-methylumbelliferyl heptanoate (MUH)) of melanoma cell lines (BLM, MV3, MEWO, and SKMel19) (a) and of melanoma cells directly isolated from excised skin metastases (b) treated with lonafarnib (lona) or/and sorafenib (sora) for 72hours. The percentage of growth inhibition compared with DMSO-treated controls is shown on the y axis (*P<0.05). (c) Real-time proliferation assay of melanoma cells (BLM) treated with DMSO as control (ctrl), lonafarnib or/and sorafenib, rapamycin (rapa) or/and sorafenib, and Triton X % as positive control for cell death. (d) Response surface analysis of melanoma cells (BLM, MV3, MEWO, and SKMel19) treated with lonafarnib and sorafenib for 72hours (+ superadditive effects). (e) Growth assay (MUH) of melanoma cells (BLM, MV3, MEWO, and SKMel19) treated with increasing concentrations of PLX4032. Journal of Investigative Dermatology  , DOI: ( /jid ) Copyright © 2011 The Society for Investigative Dermatology, Inc Terms and Conditions

4 Figure 3 Lonafarnib potentiates sorafenib-induced apoptosis of melanoma cells. (a) Cell cycle distribution of melanoma cells (BLM, MV3, MEWO, and SKMel19) and (b) human fibroblasts 48hours after treatment with DMSO as control, lonafarnib, or/and sorafenib. (c) Electron microscopy of melanoma cells (BLM) treated with DMSO as control and lonafarnib (lona) plus sorafenib (sora) for 24hours. In the control cells, cell membrane, mitochondria, and nucleus are intact (arrows). Treated cells are packed into membrane vesicles (arrows). Scale bar=2μm. (d) Western blot analysis of melanoma cells (BLM, MV3, MEWO, and SKMel19) 24hours after treatment with lonafarnib or/and sorafenib for B-cell lymphoma-2 (Bcl-2), Bcl-extra large (Bcl-xL), and myeloid cell leukemia 1 (Mcl-1). Journal of Investigative Dermatology  , DOI: ( /jid ) Copyright © 2011 The Society for Investigative Dermatology, Inc Terms and Conditions

5 Figure 3 Lonafarnib potentiates sorafenib-induced apoptosis of melanoma cells. (a) Cell cycle distribution of melanoma cells (BLM, MV3, MEWO, and SKMel19) and (b) human fibroblasts 48hours after treatment with DMSO as control, lonafarnib, or/and sorafenib. (c) Electron microscopy of melanoma cells (BLM) treated with DMSO as control and lonafarnib (lona) plus sorafenib (sora) for 24hours. In the control cells, cell membrane, mitochondria, and nucleus are intact (arrows). Treated cells are packed into membrane vesicles (arrows). Scale bar=2μm. (d) Western blot analysis of melanoma cells (BLM, MV3, MEWO, and SKMel19) 24hours after treatment with lonafarnib or/and sorafenib for B-cell lymphoma-2 (Bcl-2), Bcl-extra large (Bcl-xL), and myeloid cell leukemia 1 (Mcl-1). Journal of Investigative Dermatology  , DOI: ( /jid ) Copyright © 2011 The Society for Investigative Dermatology, Inc Terms and Conditions

6 Figure 4 Lonafarnib combined with sorafenib abrogates invasive tumor growth of melanoma cells in organotypic skin culture. BLM melanoma cells were seeded onto organotypic skin cultures and were treated with DMSO as control (ctrl), lonafarnib (lona), or/and sorafenib (sora). Organotypic skin cultures were stained with (a) hematoxylin and eosin (HE) or (b) the proliferation marker Ki67. BLM melanoma cells or Ki67-positive cells in organotypic skin cultures were counted. Mean±SD of direct counting of six high-powered fields are depicted. Scale bar=10μm. Journal of Investigative Dermatology  , DOI: ( /jid ) Copyright © 2011 The Society for Investigative Dermatology, Inc Terms and Conditions

7 Figure 5 Lonafarnib does not inhibit MAPK (mitogen-activated protein kinase) and AKT (acutely transforming retrovirus AKT8 in rodent T-cell lymphoma) signaling but does inhibit mTOR (mammalian target of rapamycin) signaling. (a) Western blot analysis of melanoma cells (BLM, MV3, MEWO, and SKMel19) 24hours after treatment with lonafarnib (lona) or sorafenib (sora) for total and phosphorylated extracellular signal-regulated kinase (ERK) and AKT. (b) RAS activity in melanoma cells (BLM, MV3, MEWO, and SKMel19) following treatment with lonafarnib for 24hours was analyzed using a RAS activation assay. Guanosine triphosphate (GTP)-bound active p21 RAS was isolated from lysates by affinity precipitation with a GST-RBD fusion protein followed by immunoblot analysis with pan-RAS antibody. The fusion protein (42kDa) was detected by Ponceau S red staining. (c) Western blot analysis of melanoma cells 24hours after treatment with lonafarnib for phosphorylated p70 S6 kinase (p-p70S6K) and S6 ribosomal protein (p-S6P). Journal of Investigative Dermatology  , DOI: ( /jid ) Copyright © 2011 The Society for Investigative Dermatology, Inc Terms and Conditions

8 Figure 6 Lonafarnib augments sorafenib-induced upregulation of p8 and CHOP (CAAT/enhancer binding protein (C/EBP) homologous protein). (a) Relative expression of p8 in melanoma cells (BLM, MV3, MEWO, and SKMel19) treated with DMSO as control (ctrl), lonafarnib (lona), or/and sorafenib (sora) for 12hours using quantitative real-time PCR. (b) Western blot analysis of melanoma cells (BLM, MV3, MEWO, and SKMel19) 24hours after treatment with lonafarnib or/and sorafenib for CHOP. (c) Growth assay (4-methylumbelliferyl heptanoate (MUH)) of melanoma cells (BLM, MV3, MEWO, and SKMel19) treated with increasing concentrations of thapsigargin for 72hours. Cell cycle distribution of melanoma cells (BLM, MV3, MEWO, and SKMel19) treated with DMSO as control and thapsigargin for 48hours. Relative expression of p8 in melanoma cells (BLM, MV3, MEWO, and SKMel19) treated with DMSO as control and thapsigargin for 12hours using quantitative real-time PCR. Journal of Investigative Dermatology  , DOI: ( /jid ) Copyright © 2011 The Society for Investigative Dermatology, Inc Terms and Conditions

9 Figure 6 Lonafarnib augments sorafenib-induced upregulation of p8 and CHOP (CAAT/enhancer binding protein (C/EBP) homologous protein). (a) Relative expression of p8 in melanoma cells (BLM, MV3, MEWO, and SKMel19) treated with DMSO as control (ctrl), lonafarnib (lona), or/and sorafenib (sora) for 12hours using quantitative real-time PCR. (b) Western blot analysis of melanoma cells (BLM, MV3, MEWO, and SKMel19) 24hours after treatment with lonafarnib or/and sorafenib for CHOP. (c) Growth assay (4-methylumbelliferyl heptanoate (MUH)) of melanoma cells (BLM, MV3, MEWO, and SKMel19) treated with increasing concentrations of thapsigargin for 72hours. Cell cycle distribution of melanoma cells (BLM, MV3, MEWO, and SKMel19) treated with DMSO as control and thapsigargin for 48hours. Relative expression of p8 in melanoma cells (BLM, MV3, MEWO, and SKMel19) treated with DMSO as control and thapsigargin for 12hours using quantitative real-time PCR. Journal of Investigative Dermatology  , DOI: ( /jid ) Copyright © 2011 The Society for Investigative Dermatology, Inc Terms and Conditions

Download ppt "The Farnesyl Transferase Inhibitor Lonafarnib Inhibits mTOR Signaling and Enforces Sorafenib-Induced Apoptosis in Melanoma Cells  Heike Niessner, Daniela."

Similar presentations

IL-18 Downregulates Collagen Production in Human Dermal Fibroblasts via the ERK Pathway  Hee Jung Kim, Seok Bean Song, Jung Min Choi, Kyung Moon Kim,

IL-18 Downregulates Collagen Production in Human Dermal Fibroblasts via the ERK Pathway  Hee Jung Kim, Seok Bean Song, Jung Min Choi, Kyung Moon Kim,
Enhanced Sensitivity to Sunitinib by Inhibition of Akt1 Expression in Human Castration- resistant Prostate Cancer PC3 Cells Both In Vitro and In Vivo 

Enhanced Sensitivity to Sunitinib by Inhibition of Akt1 Expression in Human Castration- resistant Prostate Cancer PC3 Cells Both In Vitro and In Vivo 
RanBP3 Regulates Melanoma Cell Proliferation via Selective Control of Nuclear Export  Gaurav Pathria, Bhavuk Garg, Christine Wagner, Kanika Garg, Melanie.

RanBP3 Regulates Melanoma Cell Proliferation via Selective Control of Nuclear Export  Gaurav Pathria, Bhavuk Garg, Christine Wagner, Kanika Garg, Melanie.
Stefanie Krenzer, Heike Peterziel, Cornelia Mauch, Sachiko I

Stefanie Krenzer, Heike Peterziel, Cornelia Mauch, Sachiko I
Cell Surface CD74–MIF Interactions Drive Melanoma Survival in Response to Interferon-γ  Keiji Tanese, Yuuri Hashimoto, Zuzana Berkova, Yuling Wang, Felipe.

Cell Surface CD74–MIF Interactions Drive Melanoma Survival in Response to Interferon-γ  Keiji Tanese, Yuuri Hashimoto, Zuzana Berkova, Yuling Wang, Felipe.
A Signal Transduction Pathway from TGF-β1 to SKP2 via Akt1 and c-Myc and its Correlation with Progression in Human Melanoma  Xuan Qu, Liangliang Shen,

A Signal Transduction Pathway from TGF-β1 to SKP2 via Akt1 and c-Myc and its Correlation with Progression in Human Melanoma  Xuan Qu, Liangliang Shen,
Vemurafenib Induces Senescence Features in Melanoma Cells

Vemurafenib Induces Senescence Features in Melanoma Cells
MicroRNA-31 Promotes Skin Wound Healing by Enhancing Keratinocyte Proliferation and Migration  Dongqing Li, X.I. Li, Aoxue Wang, Florian Meisgen, Andor.

MicroRNA-31 Promotes Skin Wound Healing by Enhancing Keratinocyte Proliferation and Migration  Dongqing Li, X.I. Li, Aoxue Wang, Florian Meisgen, Andor.
Neurotrophins and Their Receptors Stimulate Melanoma Cell Proliferation and Migration  Francesca Truzzi, Alessandra Marconi, Roberta Lotti, Katiuscia.

Neurotrophins and Their Receptors Stimulate Melanoma Cell Proliferation and Migration  Francesca Truzzi, Alessandra Marconi, Roberta Lotti, Katiuscia.
Yongping Shao, Kaitlyn Le, Hanyin Cheng, Andrew E. Aplin 

Yongping Shao, Kaitlyn Le, Hanyin Cheng, Andrew E. Aplin 
3,3′,4,4′,5,5′-Hexahydroxystilbene Impairs Melanoma Progression in a Metastatic Mouse Model  Verena Paulitschke, Nikolaus Schicher, Thomas Szekeres, Walter.

3,3′,4,4′,5,5′-Hexahydroxystilbene Impairs Melanoma Progression in a Metastatic Mouse Model  Verena Paulitschke, Nikolaus Schicher, Thomas Szekeres, Walter.
Resveratrol Targets Transforming Growth Factor-β2 Signaling to Block UV-Induced Tumor Progression  Kwang Ho Kim, Jung Ho Back, Yucui Zhu, Josh Arbesman,

Resveratrol Targets Transforming Growth Factor-β2 Signaling to Block UV-Induced Tumor Progression  Kwang Ho Kim, Jung Ho Back, Yucui Zhu, Josh Arbesman,
Modification of Alternative Splicing of Mcl-1 Pre-mRNA Using Antisense Morpholino Oligonucleotides Induces Apoptosis in Basal Cell Carcinoma Cells  Jeng-Jer.

Modification of Alternative Splicing of Mcl-1 Pre-mRNA Using Antisense Morpholino Oligonucleotides Induces Apoptosis in Basal Cell Carcinoma Cells  Jeng-Jer.
Dual Role of Apoptosis-Associated Speck-Like Protein Containing a CARD (ASC) in Tumorigenesis of Human Melanoma  Weimin Liu, Yuchun Luo, Jeffrey H. Dunn,

Dual Role of Apoptosis-Associated Speck-Like Protein Containing a CARD (ASC) in Tumorigenesis of Human Melanoma  Weimin Liu, Yuchun Luo, Jeffrey H. Dunn,
RanBP3 Regulates Melanoma Cell Proliferation via Selective Control of Nuclear Export  Gaurav Pathria, Bhavuk Garg, Christine Wagner, Kanika Garg, Melanie.

RanBP3 Regulates Melanoma Cell Proliferation via Selective Control of Nuclear Export  Gaurav Pathria, Bhavuk Garg, Christine Wagner, Kanika Garg, Melanie.
P90RSK Blockade Inhibits Dual BRAF and MEK Inhibitor-Resistant Melanoma by Targeting Protein Synthesis  Nicholas Theodosakis, Goran Micevic, Casey G.

P90RSK Blockade Inhibits Dual BRAF and MEK Inhibitor-Resistant Melanoma by Targeting Protein Synthesis  Nicholas Theodosakis, Goran Micevic, Casey G.
RAF Inhibition Overcomes Resistance to TRAIL-Induced Apoptosis in Melanoma Cells  Anja Berger, Sandra-Annika Quast, Michael Plötz, Nicholas-Frederik Kuhn,

RAF Inhibition Overcomes Resistance to TRAIL-Induced Apoptosis in Melanoma Cells  Anja Berger, Sandra-Annika Quast, Michael Plötz, Nicholas-Frederik Kuhn,
Complement Factor H: A Biomarker for Progression of Cutaneous Squamous Cell Carcinoma  Pilvi M. Riihilä, Liisa M. Nissinen, Risto Ala-aho, Markku Kallajoki,

Complement Factor H: A Biomarker for Progression of Cutaneous Squamous Cell Carcinoma  Pilvi M. Riihilä, Liisa M. Nissinen, Risto Ala-aho, Markku Kallajoki,
Effects of Betulinic Acid Alone and in Combination with Irradiation in Human Melanoma Cells  Edgar Selzer, Emilio Pimentel, Volker Wacheck, Werner Schlegel,

Effects of Betulinic Acid Alone and in Combination with Irradiation in Human Melanoma Cells  Edgar Selzer, Emilio Pimentel, Volker Wacheck, Werner Schlegel,
CYLD Inhibits Melanoma Growth and Progression through Suppression of the JNK/AP-1 and β1-Integrin Signaling Pathways  Hengning Ke, Christina K. Augustine,

CYLD Inhibits Melanoma Growth and Progression through Suppression of the JNK/AP-1 and β1-Integrin Signaling Pathways  Hengning Ke, Christina K. Augustine,

Similar presentations

Ads by Google